Cantor Fitzgerald Boosts Earnings Estimates for Pharvaris

Pharvaris N.V. (NASDAQ:PHVS) – Stock analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for Pharvaris in a report issued on Thursday, November 13th. Cantor Fitzgerald analyst S. Seedhouse now expects that the company will earn ($2.81) per share for the year, up from their previous forecast of ($2.87). The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. Cantor Fitzgerald also issued estimates for Pharvaris’ FY2026 earnings at ($2.61) EPS.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.08.

Other research analysts also recently issued research reports about the company. JMP Securities reduced their target price on Pharvaris from $55.00 to $52.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 13th. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Pharvaris in a research report on Thursday. Zacks Research upgraded Pharvaris from a “strong sell” rating to a “hold” rating in a research note on Monday, August 18th. Wedbush lifted their price objective on shares of Pharvaris from $27.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.57.

Pharvaris Trading Down 2.9%

Shares of NASDAQ:PHVS opened at $23.55 on Monday. The firm has a market cap of $1.23 billion, a PE ratio of -7.34 and a beta of -2.78. The company has a fifty day simple moving average of $23.20 and a 200 day simple moving average of $20.69. Pharvaris has a 12-month low of $11.51 and a 12-month high of $26.33.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new position in Pharvaris in the 2nd quarter worth approximately $57,000. JPMorgan Chase & Co. boosted its position in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Pharvaris in the third quarter worth $75,000. Legal & General Group Plc grew its stake in shares of Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares during the last quarter. Finally, California State Teachers Retirement System increased its position in Pharvaris by 9.8% during the second quarter. California State Teachers Retirement System now owns 14,048 shares of the company’s stock worth $247,000 after acquiring an additional 1,257 shares during the period.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.